NYU Langone Health’s Irwin D. Mandel Advances in Cardiovascular Risk Reduction: Improving Treatment for Patients with Diabetes
Jointly provided by NYU Grossman School of Medicine and the New York Chapter American College of Physicians
To learn more or to register, click here.
Featuring a COVID-19 Presentation and Case Conference:
Center Director and lead investigator, Dr. Jeffrey Berger, will discuss the risk of thrombosis in COVID-19 and the ongoing Antithrombotic Strategies in COVID-19 clinical trial. Dr. Berger will also present Challenging Cases in Antithrombotic Therapy, highlighting strategies to prevent clotting events in COVID-19 positive patients.
This one-day virtual course will cover state-of-the-art management of patients with cardiovascular risk factors with a focus on prevention. The morning session will highlight the latest scientific and clinical advances in the management of diabetes with topics to include epigenetics and diabetes, recent technological advances in diabetic care, and strategies to achieve cardiovascular risk reduction in diabetic patients. The course will address current approaches to treating elevated triglycerides, lipoprotein(a), ApoC3, and LDL, highlighting new studies and emerging treatment options to treat those risk factors. A presentation on cardiovascular risk factor variability will examine how variability in blood pressure, cholesterol, body weight, and other factors may predict cardiovascular risk. The landmark ISCHEMIA Trial outcomes data be presented, a trial that examined the role of revascularization in managing stable ischemic heart disease. A presentation on cardiovascular genetics will highlight the current state of cardiovascular genetics and review scientific studies that further the field to improve patient care. In addition to the lectures, attendees will participate in a lunch case conference that will focus on challenging cases in antithrombotic management.